INVA
Strong BuyUnloved QualityInnoviva, Inc. · Healthcare · United States · $1.5B cap · $19.9M/day traded
$21.45 +1.1% · close 12 Oct · scored 14 Oct
Unloved Quality: Strong and cheap; the market has not turned yet.
Read our full research report on INVA (Apr 2026), freeReport expected 4 Nov: the next-year EPS estimate has been little changed over the last 13 weeks.
As of 14 Oct 2026, MoatMap's StockRank for Innoviva, Inc. (INVA) is 93/100, ranked against 24,000+ stocks in 35 markets (Quality 74, Value 78, Momentum 45, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
ABOUT INNOVIVA, INC.
Read
Innoviva, Inc. focuses on royalties from respiratory drugs, primarily through its collaboration with GlaxoSmithKline (GSK) on therapies like Relvar/Breo Ellipta and Anoro Ellipta. The company benefits from a stable, long-term revenue stream derived from royalties on blockbuster respiratory medications, minimizing operational and R&D expenditures. It is a unique healthcare company acting primarily as a royalty aggregator, providing exposure to established drug franchises.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 331.3M | 310.5M | 358.7M | 411.3M | 7.5% | 440.0M | 451.3M | 490.0M | 9.1% |
| EPS | 3.07 | 2.75 | 0.37 | 4.02 | 9.4% | 4.28 | 2.72 | 2.76 | -17.2% |
| Shares | 69.2M | 63.3M | 62.7M | 74.6M | +7.9% | 72.2M | — | — | — |
| Debt | 544.1M | 449.1M | 451.1M | 269.0M | -20.9% | 331.2M | — | — | — |
| Equity | 565.8M | 675.0M | 691.2M | 1.2B | 27.5% | — | — | — | — |
| Op CF | 201.7M | 141.1M | 188.7M | 196.9M | -0.8% | 191.5M | — | — | — |
| Inv CF | -56.6M | -66.8M | -63.8M | 40.5M | — | — | — | — | — |
| Fin CF | -55.6M | -171.8M | -13.5M | 8.6M | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Calmer than 77% of stocks we rank over the past year (28% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of INVA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| INVA | Innoviva, Inc.(you) | $1.5B | 93 | Strong Buy |
| RIGL | Rigel Pharmaceuticals, Inc. | $899M | 98 | Strong Buy |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.4B | 100 | Strong Buy |
| ZVRA | Zevra Therapeutics, Inc. | $672M | 92 | Strong Buy |
| ABUS | Arbutus Biopharma Corporation | $961M | 81 | Strong Buy |
| CRMD | CorMedix Inc. | $599M | 98 | Strong Buy |
| PBYI | Puma Biotechnology, Inc. | $479M | 98 | Strong Buy |
| ADMA | ADMA Biologics, Inc. | $2.2B | 73 | Buy |
| MDXG | MiMedx Group, Inc. | $696M | 74 | Buy |
| 1521.HK | Frontage Holdings Corporation | $280M | 95 | Strong Buy |
Peer medians: ROE -26.1% · P/E 29.0x · Gross margin 64.2%
Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.